Pri­or­i­ty re­view vouch­er up­dates: Who's won PRVs, who's bought them, and how much they're sell­ing for

Track­er up­dat­ed on 5/14/24 to note that Day One won a rare pe­di­atric PRV for the ap­proval of Ojem­da (tovo­rafenib) for chil­dren 6 months and old­er with re­lapsed or re­frac­to­ry pe­di­atric low-grade glioma har­bor­ing a BRAF fu­sion or re­arrange­ment, or BRAF V600 mu­ta­tion. X4 Phar­ma­ceu­ti­cals on May 9 an­nounced the sale of its rare pe­di­atric dis­ease PRV for $105 mil­lion. 

The FDA can award bio­phar­ma com­pa­nies with pri­or­i­ty re­view vouch­ers (PRVs) fol­low­ing new ap­provals of treat­ments for ne­glect­ed trop­i­cal dis­eases, rare pe­di­atric dis­eases and med­ical coun­ter­mea­sures. The sys­tem by which PRVs are sold, typ­i­cal­ly for around $100 mil­lion each, con­tin­ues to thrive, more than a decade af­ter it was cre­at­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER